• 5989 Citations
  • 40 Scopus h-Index
20032019
If you made any changes in Pure, your changes will be visible here soon.

Research Output 2003 2019

2019

Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia

Ruppert, A. S., Yin, J., Davidian, M., Tsiatis, A. A., Byrd, J. C., Woyach, J. A. & Mandrekar, S. J., Apr 1 2019, In : Annals of oncology : official journal of the European Society for Medical Oncology. 30, 4, p. 542-550 9 p.

Research output: Contribution to journalArticle

Open Access
B-Cell Chronic Lymphocytic Leukemia
Maintenance
PCI 32765
Residual Neoplasm
Sample Size
1 Citation (Scopus)

Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614)

Yin, J., Laplant, B., Uy, G. L., Marcucci, G., Blum, W., Larson, R. A., Stone, R. M. & Mandrekar, S. J., Jun 11 2019, In : Blood Advances. 3, 11, p. 1714-1721 8 p.

Research output: Contribution to journalArticle

Open Access
Acute Myeloid Leukemia
Disease-Free Survival
Cell Transplantation
Random Allocation
Endpoint Determination
3 Citations (Scopus)
Phase I Trial
End point
Toxicity
Binary
Dose

Ibrutinib Regimens in Older Patients with Untreated CLL. Reply

Woyach, J. A., Ruppert, A. S. & Mandrekar, S. J., Apr 25 2019, In : The New England journal of medicine. 380, 17, p. 1680-1681 2 p.

Research output: Contribution to journalLetter

Pyrazoles
Pyrimidines
PCI 32765

Improving attribution of adverse events in oncology clinical trials

George, G. C., Barata, P. C., Campbell, A., Chen, A., Cortes, J. E., Hyman, D. M., Jones, L., Karagiannis, T., Klaar, S., Le-Rademacher, J., LoRusso, P., Mandrekar, S. J., Merino, D. M., Minasian, L. M., Mitchell, S. A., Montez, S., O'Connor, D. J., Pettit, S., Silk, E., Sloan, J. A. & 6 others, Stewart, M., Takimoto, C. H., Wong, G. Y., Yap, T. A., Cleeland, C. S. & Hong, D. S., Jun 1 2019, In : Cancer Treatment Reviews. 76, p. 33-40 8 p.

Research output: Contribution to journalReview article

Clinical Trials
Research Personnel
Causality
Translational Medical Research
Contracts
4 Citations (Scopus)
Databases
Drug Therapy
Neoplasms
Response Evaluation Criteria in Solid Tumors
Survival
2018
Dose Finding
Toxicity
Efficacy
Dose
Cycle
2 Citations (Scopus)

Application of multi-state models in cancer clinical trials

Le-Rademacher, J., Peterson, R. A., Therneau, T. M., Sanford, B. L., Stone, R. M. & Mandrekar, S. J., Jan 1 2018, (Accepted/In press) In : Clinical Trials.

Research output: Contribution to journalArticle

4'-N-benzoylstaurosporine
Clinical Trials
Proportional Hazards Models
Neoplasms
Software
2 Citations (Scopus)

Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations

Le-Rademacher, J., Dahlberg, S., Lee, J. J., Adjei, A. & Mandrekar, S. J., Nov 1 2018, In : Journal of Thoracic Oncology. 13, 11, p. 1625-1637 13 p.

Research output: Contribution to journalReview article

Lung Neoplasms
Biomarkers
Clinical Trials
Precision Medicine
Standard of Care
1 Citation (Scopus)

Evaluation of End Points in Cancer Clinical Trials

Yin, J., Dahlberg, S. E. & Mandrekar, S. J., Jan 1 2018, (Accepted/In press) In : Journal of Thoracic Oncology.

Research output: Contribution to journalArticle

Clinical Trials
Neoplasms
100 Citations (Scopus)

Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL

Woyach, J. A., Ruppert, A. S., Heerema, N. A., Zhao, W., Booth, A. M., Ding, W. D., Bartlett, N. L., Brander, D. M., Barr, P. M., Rogers, K. A., Parikh, S. A., Coutre, S., Hurria, A., Brown, J. R., Lozanski, G., Blachly, J. S., Ozer, H. G., Major-Elechi, B., Fruth, B., Nattam, S. & 11 others, Larson, R. A., Erba, H., Litzow, M. R., Owen, C., Kuzma, C., Abramson, J. S., Little, R. F., Smith, S. E., Stone, R. M., Mandrekar, S. J. & Byrd, J. C., Dec 27 2018, In : New England Journal of Medicine. 379, 26, p. 2517-2528 12 p.

Research output: Contribution to journalArticle

B-Cell Chronic Lymphocytic Leukemia
Disease-Free Survival
PCI 32765
Rituximab
Clinical Trials Data Monitoring Committees
2 Citations (Scopus)

Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)

Byrd, J. C., Ruppert, A. S., Heerema, N. A., Halvorson, A. E., Hoke, E., Smith, M. R., Godwin, J. E., Couban, S., Fehniger, T. A., Thirman, M. J., Tallman, M. S., Appelbaum, F. R., Stone, R. M., Robinson, S., Chang, J. E., Mandrekar, S. J. & Larson, R. A., Jul 24 2018, In : Blood advances. 2, 14, p. 1705-1718 14 p.

Research output: Contribution to journalArticle

B-Cell Chronic Lymphocytic Leukemia
Confidence Intervals
Disease-Free Survival
Survival Rate
lenalidomide
4 Citations (Scopus)

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)

Roboz, G. J., Mandrekar, S. J., Desai, P., Laumann, K., Walker, A. R., Wang, E. S., Kolitz, J. E., Powell, B. L., Attar, E. C., Stock, W., Bloomfield, C. D., Kohlschmidt, J., Mrózek, K., Hassane, D. C., Garraway, L., Jané-Valbuena, J., Baltay, M., Tracy, A., Marcucci, G., Stone, R. M. & 1 others, Larson, R. A., Dec 26 2018, In : Blood advances. 2, 24, p. 3608-3617 10 p.

Research output: Contribution to journalArticle

decitabine
Acute Myeloid Leukemia
Cytogenetics
Febrile Neutropenia
Survival
2017
21 Citations (Scopus)

A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001

Uy, G. L., Mandrekar, S. J., Laumann, K., Marcucci, G., Zhao, W., Levis, M. J., Klepin, H. D., Baer, M. R., Powell, B. L., Westervelt, P., DeAngelo, D. J., Stock, W., Sanford, B., Blum, W. G., Bloomfield, C. D., Stone, R. M. & Larson, R. A., Jan 24 2017, In : Blood Advances. 1, 5, p. 331-340 10 p.

Research output: Contribution to journalArticle

Acute Myeloid Leukemia
Protein-Tyrosine Kinases
Leukemia
Drug Therapy
Neoplasms
2 Citations (Scopus)

Comparison of futility monitoring guidelines using completed phase III oncology trials

Zhang, Q., Freidlin, B., Korn, E. L., Halabi, S., Mandrekar, S. J. & Dignam, J. J., Feb 1 2017, In : Clinical Trials. 14, 1, p. 48-58 11 p.

Research output: Contribution to journalArticle

Medical Futility
Guidelines
Phase III Clinical Trials
Sample Size
Confidence Intervals
3 Citations (Scopus)

Definitions and statistical properties of master protocols for personalized medicine in oncology

Renfro, L. A. & Mandrekar, S. J., Oct 10 2017, (Accepted/In press) In : Journal of Biopharmaceutical Statistics. p. 1-12 12 p.

Research output: Contribution to journalArticle

Oncology
Precision Medicine
Medicine
Statistical property
Decision Support Techniques
385 Citations (Scopus)

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

RECIST working group, Mar 1 2017, In : The Lancet Oncology. 18, 3, p. e143-e152

Research output: Contribution to journalReview article

Guidelines
Immunotherapy
Neoplasms
Disease Progression
Therapeutics
21 Citations (Scopus)

Keyboard: A novel Bayesian toxicity probability interval design for phase I clinical trials

Yan, F., Mandrekar, S. J. & Yuan, Y., Aug 1 2017, In : Clinical Cancer Research. 23, 15, p. 3994-4003 10 p.

Research output: Contribution to journalArticle

Clinical Trials, Phase I
Poisons
Software
445 Citations (Scopus)

Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 Mutation

Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., Thiede, C., Prior, T. W., Dohner, K., Marcucci, G., Lo-Coco, F., Klisovic, R. B., Wei, A., Sierra, J., Sanz, M. A., Brandwein, J. M., De Witte, T., Niederwieser, D., Appelbaum, F. R., Medeiros, B. C. & 9 others, Tallman, M. S., Krauter, J., Schlenk, R. F., Ganser, A., Serve, H., Ehninger, G., Amadori, S., Larson, R. A. & Dohner, H., Aug 3 2017, In : New England Journal of Medicine. 377, 5, p. 454-464 11 p.

Research output: Contribution to journalArticle

4'-N-benzoylstaurosporine
Acute Myeloid Leukemia
Drug Therapy
Mutation
Placebos
2 Citations (Scopus)

Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data

Yin, J., Paoletti, X., Sargent, D. J. & Mandrekar, S. J., Dec 1 2017, In : Clinical Trials. 14, 6, p. 611-620 10 p.

Research output: Contribution to journalArticle

Therapeutics
Aptitude
Maximum Tolerated Dose
Immunotherapy
Linear Models
5 Citations (Scopus)
Controlled Clinical Trials
Placebos
Research
Therapeutics
Neoplasms
2016
3 Citations (Scopus)

A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles

Yin, J., Qin, R., Ezzalfani, M., Sargent, D. J. & Mandrekar, S. J., 2016, (Accepted/In press) In : Statistics in Medicine.

Research output: Contribution to journalArticle

Dose Finding
Toxicity
Cycle
Continual Reassessment Method
Quasi-likelihood
21 Citations (Scopus)

An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia

Stock, W., Diouf, B., Crews, K., Pei, D., Cheng, C., Laumann, K., Mandrekar, S. J., Luger, S., Advani, A., Stone, R., Larson, R. & Evans, W., 2016, (Accepted/In press) In : Clinical Pharmacology and Therapeutics.

Research output: Contribution to journalArticle

Vincristine
Peripheral Nervous System Diseases
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Genotype
National Cancer Institute (U.S.)
22 Citations (Scopus)

A Nomogram to Predict Recurrence and Survival of High-Risk Patients Undergoing Sublobar Resection for Lung Cancer: An Analysis of a Multicenter Prospective Study (ACOSOG Z4032)

Kent, M. S., Mandrekar, S. J., Landreneau, R., Nichols, F., Foster, N. R., DiPetrillo, T. A., Meyers, B., Heron, D. E., Jones, D. R., Tan, A. D., Starnes, S., Putnam, J. B. & Fernando, H. C., 2016, (Accepted/In press) In : Annals of Thoracic Surgery.

Research output: Contribution to journalArticle

Nomograms
Multicenter Studies
Lung Neoplasms
Prospective Studies
Recurrence
13 Citations (Scopus)

A Randomized Phase IIb Trial of myo-Inositol in Smokers with Bronchial Dysplasia

Lam, S., Mandrekar, S. J., Gesthalter, Y., Allen Ziegler, K. L., Seisler, D. K., Midthun, D. E., Mao, J. T., Aubry, M. C., McWilliams, A., Sin, D. D., Shaipanich, T., Liu, G., Johnson, E., Bild, A., Lenburg, M. E., Ionescu, D. N., Mayo, J., Yi, J., Tazelaar, H., Harmsen, W. S. & 5 others, Smith, J., Spira, A. E., Beane, J., Limburg, P. J. & Szabo, E., Dec 1 2016, In : Cancer Prevention Research. 9, 12, p. 906-914 9 p.

Research output: Contribution to journalArticle

Inositol
Placebos
Bronchoalveolar Lavage Fluid
Bronchoscopy
Phosphatidylinositol 3-Kinases
22 Citations (Scopus)

Clinical trial designs incorporating predictive biomarkers

Renfro, L. A., Mallick, H., An, M. W., Sargent, D. J. & Mandrekar, S. J., 2016, In : Cancer Treatment Reviews. 43, p. 74-82 9 p.

Research output: Contribution to journalArticle

Biomarkers
Clinical Trials
Neoplasms
Standard of Care
Cell Survival
7 Citations (Scopus)

Difference in restricted mean survival time for cost-effectiveness analysis using individual patient data meta-analysis: Evidence from a case study

MAR-LC Collaborative Group & Schild, S. E., Mar 1 2016, In : PLoS One. 11, 3, e0150032.

Research output: Contribution to journalArticle

cost effectiveness
Cost effectiveness
Metadata
meta-analysis
Cost-Benefit Analysis
33 Citations (Scopus)

Enrollment trends and disparity among patients with lung cancer in national clinical trials, 1990 to 2012

Pang, H. H., Wang, X., Stinchcombe, T. E., Wong, M. L., Cheng, P., Ganti, A. K., Sargent, D. J., Zhang, Y., Hu, C., Mandrekar, S. J., Redman, M. W., Manola, J. B., Schilsky, R. L., Cohen, H. J., Bradley, J. D., Adjei, A., Gandara, D., Ramalingam, S. S. & Vokes, E. E., Nov 20 2016, In : Journal of Clinical Oncology. 34, 33, p. 3992-3999 8 p.

Research output: Contribution to journalArticle

Lung Neoplasms
Clinical Trials
Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
Population
7 Citations (Scopus)

Impact of Sublobar Resection on Pulmonary Function: Long-Term Results from American College of Surgeons Oncology Group Z4032 (Alliance)

Kent, M. S., Mandrekar, S. J., Landreneau, R., Nichols, F., DiPetrillo, T. A., Meyers, B., Heron, D. E., Jones, D. R., Tan, A. D., Starnes, S., Putnam, J. B. & Fernando, H. C., 2016, (Accepted/In press) In : Annals of Thoracic Surgery.

Research output: Contribution to journalArticle

Lung
Thoracotomy
Lung Volume Measurements
Brachytherapy
Forced Expiratory Volume
19 Citations (Scopus)

Precision oncology: A new era of cancer clinical trials

Renfro, L. A., An, M. W. & Mandrekar, S. J., 2016, (Accepted/In press) In : Cancer Letters.

Research output: Contribution to journalArticle

Clinical Trials
Biomarkers
Neoplasms
Mutation
Tumor Biomarkers
43 Citations (Scopus)

RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group

Schwartz, L. H., Seymour, L., Litière, S., Ford, R., Gwyther, S., Mandrekar, S. J., Shankar, L., Bogaerts, J., Chen, A., Dancey, J., Hayes, W., Hodi, F. S., Hoekstra, O. S., Huang, E. P., Lin, N., Liu, Y., Therasse, P., Wolchok, J. D. & de Vries, E., Mar 25 2016, (Accepted/In press) In : European Journal of Cancer.

Research output: Contribution to journalArticle

Clinical Trials
Response Evaluation Criteria in Solid Tumors
Immunotherapy
Multicenter Studies
Meta-Analysis
115 Citations (Scopus)

RECIST 1.1-Update and clarification: From the RECIST committee

Schwartz, L. H., Litière, S., de Vries, E., Ford, R., Gwyther, S., Mandrekar, S. J., Shankar, L., Bogaerts, J., Chen, A., Dancey, J., Hayes, W., Hodi, F. S., Hoekstra, O. S., Huang, E. P., Lin, N., Liu, Y., Therasse, P., Wolchok, J. D. & Seymour, L., Mar 25 2016, (Accepted/In press) In : European Journal of Cancer.

Research output: Contribution to journalArticle

Disease Progression
Publications
Lymph Nodes
Guidelines
Response Evaluation Criteria in Solid Tumors

Time to progression ratio: Promising new metric or just another metric?

An, M. W. & Mandrekar, S. J., Oct 1 2016, In : Annals of Translational Medicine. 4, S43.

Research output: Contribution to journalComment/debate

2015
39 Citations (Scopus)

Alchemist trials: A golden opportunity to transform outcomes in early-stage non-small cell lung cancer

Govindan, R., Mandrekar, S. J., Gerber, D. E., Oxnard, G. R., Dahlberg, S. E., Chaft, J., Malik, S., Mooney, M., Abrams, J. S., Jänne, P. A., Gandara, D. R., Ramalingam, S. S. & Vokes, E. E., Dec 15 2015, In : Clinical Cancer Research. 21, 24, p. 5439-5444 6 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Lung Neoplasms
Mutation
Epidermal Growth Factor Receptor
Therapeutics
31 Citations (Scopus)

Analysis of longitudinal quality-of-life data in high-risk operable patients with lung cancer: Results from the ACOSOG Z4032 (Alliance) multicenter randomized trial

Fernando, H. C., Landreneau, R. J., Mandrekar, S. J., Nichols, F. C., Dipetrillo, T. A., Meyers, B. F., Heron, D. E., Hillman, S. L., Jones, D. R., Starnes, S. L., Tan, A. D., Daly, B. D. T. & Putnam, J. B., Mar 1 2015, In : Journal of Thoracic and Cardiovascular Surgery. 149, 3, p. 718-726 9 p.

Research output: Contribution to journalArticle

Multicenter Studies
Video-Assisted Thoracic Surgery
Lung Neoplasms
Dyspnea
Quality of Life
4 Citations (Scopus)

Clinical utility of metrics based on tumor measurements in phase II trials to predict overall survival outcomes in phase III trials by using resampling methods

An, M. W., Han, Y., Meyers, J. P., Bogaerts, J., Sargent, D. J. & Mandrekar, S. J., Dec 1 2015, In : Journal of Clinical Oncology. 33, 34, p. 4048-4057 10 p.

Research output: Contribution to journalArticle

Neoplasms
Phase II Clinical Trials
Tumor Burden
Proportional Hazards Models
Response Evaluation Criteria in Solid Tumors
10 Citations (Scopus)

Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: The ALCHEMIST trials

Alden, R. S., Mandrekar, S. J. & Oxnard, G. R., 2015, In : Chinese Clinical Oncology. 4, 3, 37.

Research output: Contribution to journalArticle

Lung Neoplasms
Non-Small Cell Lung Carcinoma
Genotype
Placebos
Epidermal Growth Factor Receptor
9 Citations (Scopus)

Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival

Response Evaluation Criteria in Solid Tumors Steering Committee & Sargent, D. J., Nov 1 2015, In : Journal of the National Cancer Institute. 107, 11

Research output: Contribution to journalArticle

Survival
Neoplasms
Non-Small Cell Lung Carcinoma
Breast Neoplasms
Colorectal Neoplasms
36 Citations (Scopus)
Clinical Trials
Histology
Therapeutics
Precision Medicine
National Cancer Institute (U.S.)

Introduction to special issue on biomarker-based clinical trial designs in oncology

Sargent, D. J., Mandrekar, S. J. & Grothey, A. F., 2015, In : Chinese Clinical Oncology. 4, 3, 28.

Research output: Contribution to journalArticle

Molecular Targeted Therapy
Medical Oncology
Drug Monitoring
Drug Discovery
Tumor Biomarkers
25 Citations (Scopus)

Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's Esophagus

Chak, A., Buttar, N. S., Foster, N. R., Seisler, D. K., Marcon, N. E., Schoen, R., Cruz-Correa, M. R., Falk, G. W., Sharma, P., Hur, C., Katzka, D. A., Rodriguez, L. M., Richmond, E., Sharma, A. N., Smyrk, T. C., Mandrekar, S. J. & Limburg, P. J., Apr 1 2015, In : Clinical Gastroenterology and Hepatology. 13, 4, p. 665-672 8 p.

Research output: Contribution to journalArticle

Barrett Esophagus
Metformin
Cell Proliferation
Placebos
Insulin
9 Citations (Scopus)

Molecular and clinical implementations of ovarian cancer mouse avatar models

Zayed, A. A., Mandrekar, S. J. & Haluska, P., 2015, In : Chinese Clinical Oncology. 4, 3, 30.

Research output: Contribution to journalArticle

Ovarian Neoplasms
Heterografts
Neoplasms
Therapeutics
Pharmaceutical Preparations
19 Citations (Scopus)

Multitrial evaluation of progression-free survival as a surrogate end point for overall survival in first-line extensive-stage small-cell lung cancer

Foster, N. R., Renfro, L. A., Schild, S. E., Redman, M. W., Wang, X. F., Dahlberg, S. E., Ding, K., Bradbury, P. A., Ramalingam, S. S., Gandara, D. R., Shibata, T., Saijo, N., Vokes, E. E., Adjei, A. & Mandrekar, S. J., Jul 4 2015, In : Journal of Thoracic Oncology. 10, 7, p. 1099-1106 8 p.

Research output: Contribution to journalArticle

Small Cell Lung Carcinoma
Disease-Free Survival
Biomarkers
Survival
Validation Studies
1 Citation (Scopus)

Radiotherapy for extensive stage small-cell lung cancer

Mansfield, A. & Mandrekar, S. J., Apr 4 2015, In : The Lancet. 385, 9975, p. 1291 1 p.

Research output: Contribution to journalArticle

Small Cell Lung Carcinoma
Lung Neoplasms
Radiotherapy
2 Citations (Scopus)

The direct assignment option as a modular design component: An example for the setting of two predefined subgroups

An, M. W., Lu, X., Sargent, D. J. & Mandrekar, S. J., Jan 15 2015, In : Computational and Mathematical Methods in Medicine. 2015, 210817.

Research output: Contribution to journalArticle

Modular Design
Assignment
Subgroup
Random Allocation
Therapeutics
2014
21 Citations (Scopus)

A Phase I/II Study of Bortezomib in Combination with Paclitaxel, Carboplatin and Concurrent Thoracic Radiation Therapy for Non-Small Cell Lung Cancer: NCCTG-N0321

Zhao, Y., Foster, N. R., Meyers, J. P., Thomas, S. P., Northfelt, D. W., Rowland, K. M., Mattar, B. I., Johnson, D. B., Molina, J. R., Mandrekar, S. J., Schild, S. E., Bearden, J. D., Aubry, M. C. & Adjei, A., Sep 22 2014, (Accepted/In press) In : Journal of Thoracic Oncology.

Research output: Contribution to journalArticle

Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Radiotherapy
Thorax
20 Citations (Scopus)

Dose-finding trial designs for combination therapies in oncology

Mandrekar, S. J., Jan 10 2014, In : Journal of Clinical Oncology. 32, 2, p. 65-67 3 p.

Research output: Contribution to journalArticle

Antineoplastic Combined Chemotherapy Protocols
ErbB-2 Receptor
Neoplasms
Therapeutics
7 Citations (Scopus)

Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine

Mandrekar, S. J. & Sargent, D. J., 2014, In : Chinese Clinical Oncology. 3, 2, 14.

Research output: Contribution to journalReview article

Precision Medicine
Drug Design
Biomarkers
Clinical Trials
Therapeutics
2 Citations (Scopus)
Maximum Tolerated Dose
Genotype
Safety
Proxy
Therapeutic Uses
26 Citations (Scopus)

Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse

Mandrekar, S. J., An, M. W., Meyers, J., Grothey, A. F., Bogaerts, J. & Sargent, D. J., Mar 10 2014, In : Journal of Clinical Oncology. 32, 8, p. 841-850 10 p.

Research output: Contribution to journalArticle

Neoplasms
Breast Neoplasms
Response Evaluation Criteria in Solid Tumors
Survival
Proportional Hazards Models